APO 010 companion diagnostic - Oncology Venture

Drug Profile

APO 010 companion diagnostic - Oncology Venture

Alternative Names: APO010 DRP™

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncology Venture
  • Developer Medical Prognosis Institute; Oncology Venture
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 07 Oct 2016 Oncology Venture in-licenses Drug Response Prediction (DRP™) technology from Medical Prognosis Institute before October 2016 (Oncology Venture website, October 2016),
  • 07 Oct 2016 Phase-II clinical trials in Multiple myeloma (Diagnosis) in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top